JCAD publishes results from clincal study of Tria Skin Perfecting Blue Light for acne

The Journal of Clinical and Aesthetic Dermatology (JCAD), a respected peer-reviewed dermatology publication, has, in its May 2012 issue, published the results of a single-center study of the Tria Skin Perfecting Blue Light for acne, showcasing the overall effectiveness of the device in significantly reducing the amount of acne, as well as the frequency, severity and redness of acne flares. The device utilizes high intensity blue light, comparable to that available in dermatologists' offices since 2002, to eliminate acne-causing bacteria at its source, and can be used safely and effectively at home.

The Journal of Clinical and Aesthetic Dermatology (JCAD) is a monthly peer-reviewed publication for practicing dermatologists, providing pertinent information and offering its readers original research, comprehensive reviews, provocative commentaries, and informative reports by key opinion leaders and practicing clinicians.

Participants in the single-center, open-label eight week study, conducted by Ronald Wheeland, M.D. and Andrea Koreck, M.D., Ph.D., included 32 men and women between the ages of 13 and 45 years with mild to moderate facial acne vulgaris.  Treatment of breakout areas with the Skin Perfecting Blue Light resulted in a statistically significant (P</-0.01) reduction in inflammatory lesions as early as Week 1 vs baseline.  Further, 100 percent of subjects reported improvement in the frequency and severity of their flares after eight weeks of using the Tria Skin Perfecting Blue Light, as compared with baseline.  A majority of study participants also reported significant improvements in skin clarity, tone, texture and smoothness after using Tria's blue light device.

"The Tria Skin Perfecting Blue Light delivers a highly efficacious and gentle treatment for acne without concerns of irritation and antibiotic resistance.  It can be used alone to treat breakouts, or incorporated into an existing OTC or RX regimen for added efficacy," said Andrea Koreck, M.D., Ph.D. clinical study investigator.

The Skin Perfecting Blue Light has also recently received its medical CE marking, signifying that it meets the Medical Device Directive of the European Union, as well as its regulatory approval by the Korean KFDA.

"The foundation of our company and brand is rooted in evidence-based science and the publication of this study serves to further highlight our commitment to offering safe, effective, and clinically proven light-based skin care solutions to the global marketplace," commented Tria Beauty, Inc. CEO Kevin Appelbaum.